Trending

Divi's Labs In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

NDTV - Trending·23 Sep 2026
Divi's Labs In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

Citi said Divi's has an integrated and cost-efficient peptide manufacturing platform, which could provide an advantage as demand for peptide-based therapies expands.

More news in Trending